BioGend Therapeutics Co., Ltd. Share Price
Equities
6733
TW0006733009
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
37 TWD | +1.37% | +1.51% | -3.27% |
Sales 2024 * | 150M 4.62M 385M | Sales 2025 * | - | Capitalization | 4.55B 140M 11.7B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 30.4 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.03% |
1 day | +1.37% | ||
1 week | +1.51% | ||
1 month | +1.37% | ||
3 months | -6.45% | ||
6 months | -11.16% | ||
Current year | -3.27% |
Managers | Title | Age | Since |
---|---|---|---|
Te Li Chen
CEO | Chief Executive Officer | 55 | 07/16/07 |
Tsang Cheng Lin
CEO | Chief Executive Officer | - | 30/18/30 |
Shu Wei Chao
DFI | Director of Finance/CFO | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Jung Chin Lin
BRD | Director/Board Member | 70 | 20/19/20 |
Hai Yi Ma
BRD | Director/Board Member | - | 20/18/20 |
Te Li Chen
CEO | Chief Executive Officer | 55 | 07/16/07 |
Date | Price | Change | Volume |
---|---|---|---|
31/24/31 | 37 | +1.37% | 154,743 |
30/24/30 | 36.5 | -2.14% | 216,017 |
29/24/29 | 37.3 | +3.18% | 391,347 |
28/24/28 | 36.15 | -0.96% | 249,898 |
27/24/27 | 36.5 | +0.14% | 110,110 |
End-of-day quote Taipei Exchange, May 31, 2024
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.27% | 140M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- 6733 Stock